Medical Condition News

RSS

Study shows attaching prostheses to titanium implant improves quality of life

Today sees the presentation of a study that, for the first time, shows the results of treatment using prostheses attached to titanium implants in the bones of patients with above-the-knee amputations. It reveals that the treatment improves function and quality of life in nine out of ten patients, and is the result of research carried out at the Sahlgrenska Academy and Sahlgrenska University Hospital that is being presented this week at the International Society of Orthopaedic Surgery and Traumatology (SICOT) annual international conference in Gothenburg.

13 Sep 2010

Researchers elucidate Qua1 spatial structure region of Sam68 protein

Using NMR spectroscopy, Professor Michael Sattler and his team elucidated the spatial structure of the Qua1 region of Sam68, which is responsible for the dimerization of the protein. In collaboration with the research group of Professor Ruth Brack-Werner of the Institute of Virology, the authors showed that this region is essential for the biological function of Sam68.

13 Sep 2010

Researchers develop GAL4/UAS system to study human neurological diseases

A team of University of Oklahoma researchers studying neurobiology in fruit flies (Drosophila) has developed a new method for understanding brain function with potential applications in studies of human neurological diseases.

13 Sep 2010

Genmab announces Phase II ofatumumab study results in RRMS patients

Genmab A/S announced today encouraging results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis (RRMS).

13 Sep 2010

Advaxis publishes research article on Her2 antigen for Listeria vaccine

Scientists at Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, recently had their research using ADXS31-164, a live Listeria vaccine that targets Her2, published in a leading peer reviewed journal (Shahabi, et al 2010 Cancer Gene Therapy epublished ahead of print).

13 Sep 2010

Pennsylvania Bio issues new report on Pennsylvania's bioscience companies' efforts for cancer research

Pennsylvania Bio today issued a new report on cancer that details the research happening through Pennsylvania companies to develop new products to diagnose and treat cancer.

12 Sep 2010

New neurological deficit behind amblyopia

Researchers at New York University's Center for Neural Science have identified a new neurological deficit behind amblyopia, or "lazy eye." Their findings, which appear in the most recent issue of the Journal of Neuroscience, shed additional light on how amblyopia results from disrupted links between the brain and normal visual processing.

10 Sep 2010

Johns Hopkins added as second clinical trial site in Tengion Neo-Urinary Conduit Phase I clinical trial

Tengion, Inc., a leader in regenerative medicine, announced today it has added The Johns Hopkins Hospital in Baltimore, Maryland as a second clinical trial site for its Phase I clinical trial of the Company's lead product candidate, the Tengion Neo-Urinary Conduit™, in bladder cancer patients requiring bladder removal.

10 Sep 2010

Resverlogix announces key changes to Phase 2 ASSURE trial

Resverlogix Corp. announces that the Company's Phase 2 clinical trial, called ASSURE (ApoA-1 Synthesis Stimulation in Acute Coronary Syndrome patients), has made important modifications to the design of the trial which have the potential to demonstrate a more powerful endpoint for the planning of future clinical trials for RVX-208.

10 Sep 2010

Lantheus Medical Imaging supports FDA action to ensure appropriate use of gadolinium-based contrast agents

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, supports the U.S. Food and Drug Administration's (FDA) announcement requiring safety-related label changes for all gadolinium-based contrast agents to highlight the rare and potentially fatal condition known as nephrogenic systemic fibrosis (NSF).

10 Sep 2010

NAADAC and Hazelden partner to improve treatment for co-occurring disorders

NAADAC, the Association for Addiction Professionals, and Hazelden, the national nonprofit focused on addiction treatment, prevention and recovery announced today a new strategic partnership focused on improving the treatment of co-occurring disorders. The partnership announcement was made by NAADAC Executive Director Cynthia Moreno Tuohy during the National Conference on Addiction Disorders in Washington, D.C.

10 Sep 2010

Varian to highlight new TrueBeam medical linear accelerator at ESTRO 2010

Varian Medical Systems is spotlighting its new TrueBeam™ medical linear accelerator for fast, powerful and efficient cancer treatments at the European Society for Therapeutic Radiology and Oncology exhibition in Barcelona next week. A fully-featured TrueBeam system will be the centerpiece of Varian's booth at the annual ESTRO meeting (Booth No. 320).

10 Sep 2010

Harris Teeter to distribute Oragenics' EvoraPlus and EvoraKids oral care probiotics

Florida-based biopharmaceutical company Oragenics, Inc. has announced the continued retail expansion of its oral care probiotics EvoraPlus and EvoraKids™ with an initial order from Harris Teeter. It is anticipated that the products will be available at Harris Teeter stores in September 2010.

10 Sep 2010

Legal and moral reasons prevent most Oregon hospices from participation in 'Death with Dignity Act'

A survey in the latest issue of the Hastings Center Report found that most hospices in Oregon, the first state to legalize physician-assistance in dying, either do not participate in or have limited participation in requests for such assistance. Both legal and moral reasons are identified.

10 Sep 2010

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology, Inc., today announced that it has unblinded the Phase 3 study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer (also referred to as castration-resistant prostate cancer) whose disease has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel.

10 Sep 2010

Current treatment strategies for mood and addictive disorders

Sober Living in Delray, Recovery Residences, in conjunction with the "Moment of Change - Intervention Approaches for Professionals - 32nd National Conference" is sponsoring the presentation of "Mood Disorders and Addictive Disorders: Current Treatment Strategies" at 7:00 PM on Wednesday, September 29th, 2010 at the Old Calypso Restaurant in Delray Beach, Florida.

10 Sep 2010

Nucletron to present innovative cancer treatment during ESTRO29

Nucletron, a leading provider of state of the art radiotherapy solutions for cancer treatment, today announced a large number of exciting innovations for precise cancer treatment that will be in the spotlight during ESTRO29 in Barcelona. The company will be showcasing the latest developments in cancer treatment solutions for both brachytherapy and external beam.

10 Sep 2010

Cancer Research UK launches world's first urban running lane on London's Southbank

Dawdling pedestrians test the patience of over a quarter of outdoor runners (27 per cent) according to a poll of 1,000 runners by Cancer Research UK, to launch its Run10k series. The results have been highlighted as the charity launches the world's first urban running lane on London's Southbank with the help of celebrity runner Nell McAndrew.

10 Sep 2010

Scottish government proposes minimum price to tackle alcohol misuse

The Scottish government has confirmed that it proposes to introduce a minimum price of 45p per unit of alcohol, in order to tackle alcohol misuse and prevent related illnesses.

10 Sep 2010

'Seeking mental health treatment' is not a criteria for revocation of security clearance

Yesterday, presumably in response to a series of articles in the September issue of the Foreign Service Journal, Secretary of State Clinton issued an internal statement urging employees needing mental health treatment to get it, stating quite clearly that no Foreign Service Officer had ever lost a security clearance due to having sought mental health treatment. Concerned Foreign Service Officers wants to set the record straight.

10 Sep 2010

Medical Condition News

Study shows attaching prostheses to titanium implant improves quality of life

Researchers elucidate Qua1 spatial structure region of Sam68 protein

Researchers develop GAL4/UAS system to study human neurological diseases

Genmab announces Phase II ofatumumab study results in RRMS patients

Advaxis publishes research article on Her2 antigen for Listeria vaccine

Pennsylvania Bio issues new report on Pennsylvania's bioscience companies' efforts for cancer research

New neurological deficit behind amblyopia

Johns Hopkins added as second clinical trial site in Tengion Neo-Urinary Conduit Phase I clinical trial

Resverlogix announces key changes to Phase 2 ASSURE trial

Lantheus Medical Imaging supports FDA action to ensure appropriate use of gadolinium-based contrast agents

NAADAC and Hazelden partner to improve treatment for co-occurring disorders

Varian to highlight new TrueBeam medical linear accelerator at ESTRO 2010

Harris Teeter to distribute Oragenics' EvoraPlus and EvoraKids oral care probiotics

Legal and moral reasons prevent most Oregon hospices from participation in 'Death with Dignity Act'

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

Current treatment strategies for mood and addictive disorders

Nucletron to present innovative cancer treatment during ESTRO29

Cancer Research UK launches world's first urban running lane on London's Southbank

Scottish government proposes minimum price to tackle alcohol misuse

'Seeking mental health treatment' is not a criteria for revocation of security clearance

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News